ImmunityBio, Inc.（股票代码：IBRX）今日盘前股价大幅上涨28.58%，创下近期新高。
消息面上，该公司宣布其研发的非化疗CD19靶向CAR-NK细胞疗法在华氏巨球蛋白血症患者中实现了持续15个月的持久性完全缓解。这一突破性成果标志着该疗法在血液肿瘤治疗领域取得重大进展，为化疗不耐受患者提供了新的治疗选择。
临床数据显示，接受该疗法的患者不仅达到深度缓解状态，且在15个月随访期内未出现疾病复发迹象。与传统CAR-T疗法不同，此项疗法采用自然杀伤细胞作为载体，结合CD19靶向嵌合抗原受体技术，在避免化疗毒副作用的同时激活患者自身免疫系统。这一成果为B细胞恶性肿瘤的免疫治疗开辟了新路径，具有重大临床意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.